Voluntary Lot Withdrawals of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) for Increased Reports of Allergic/Hypersensitivity Reactions

RegulatoryImmune Globulin Intravenous (IGIV)Immune Globulin Subcutaneous (IGSC)Negative

AI Analysis

Summary

Multiple lots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) have been voluntarily withdrawn by manufacturers as a precautionary measure due to increased reports of allergic and hypersensitivity reactions. The announcement was issued to healthcare professionals on August 14, 2026.

Outcome Details

Voluntary lot withdrawal due to increased reports of allergic/hypersensitivity reactions

Importance:4/10

Sentiment:

-0.60

product safetyvoluntary withdrawaladverse eventsallergic reactionsimmunoglobulin

Related Companies

$HIT

Read the original article

Published by Drugs.com FDA MedWatch Alerts on August 14, 2026 1:25 PM

Read Original